| Schizophrenia

Abilify Maintena vs Cobenfy

Side-by-side clinical, coverage, and cost comparison for schizophrenia.
Deep comparison between: Abilify Maintena vs Cobenfy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsCobenfy has a higher rate of injection site reactions vs Abilify Maintena based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cobenfy but not Abilify Maintena, including UnitedHealthcare
Sign up to reveal the full AI analysis
Abilify Maintena
Cobenfy
At A Glance
IM injection
Every 4 weeks
Dopamine D2 partial agonist
Oral
Twice daily
Muscarinic agonist/antagonist combination
Indications
  • Schizophrenia
  • Bipolar I disorder
  • Schizophrenia
Dosing
Schizophrenia, Bipolar I disorder 400 mg IM injection monthly (deltoid or gluteal); reduce to 300 mg if adverse reactions occur; initiate via 1-day (two 400 mg injections + single oral aripiprazole 20 mg) or 14-day (one 400 mg injection + 14 days oral aripiprazole) protocol; CYP2D6 poor metabolizers start and maintain at 300 mg monthly.
Schizophrenia Starting dose 50 mg/20 mg orally twice daily for at least 2 days, then 100 mg/20 mg twice daily for at least 5 days; may increase to 125 mg/30 mg twice daily based on tolerability and response (maximum dose); take at least 1 hour before or 2 hours after a meal; do not open capsules. Geriatric patients: start at 50 mg/20 mg twice daily, maximum 100 mg/20 mg twice daily.
Contraindications
  • Known hypersensitivity to aripiprazole
  • Urinary retention
  • Moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment
  • Gastric retention
  • History of hypersensitivity to COBENFY or trospium chloride
  • Untreated narrow-angle glaucoma
Adverse Reactions
Most common (>=5%) Increased weight, akathisia, injection site pain, sedation
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, leukopenia, neutropenia, agranulocytosis, seizures, orthostatic hypotension
Postmarketing Anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria, oropharyngeal spasm, pathological gambling, hiccups, blood glucose fluctuation, DRESS, fecal incontinence
Most common (>=5%) Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease
Serious Urinary retention, liver enzyme elevations, increases in heart rate, angioedema
Postmarketing Chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope, gastritis, rash, rhabdomyolysis, confusion, delirium, hallucinations, somnolence, vision abnormal, angioedema, anaphylactic reaction, Stevens-Johnson syndrome (reported with trospium chloride component)
Pharmacology
Aripiprazole is an atypical antipsychotic whose efficacy may be mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
Xanomeline is a muscarinic agonist with preferential activity at M1 and M4 receptors in the central nervous system, where its efficacy in schizophrenia is thought to arise; trospium chloride is a peripheral muscarinic antagonist included to reduce cholinergic adverse effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abilify Maintena
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
View full coverage details ›
Cobenfy
  • Covered on 5 commercial plans
  • PA (12/12) · Step Therapy (8/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Abilify Maintena
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Cobenfy
  • Covered on 4 commercial plans
  • PA (8/8) · Step Therapy (8/8) · Qty limit (2/8)
View full coverage details ›
Humana
Abilify Maintena
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
View full coverage details ›
Cobenfy
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Cancer-Related Behavioral Health
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Cobenfy Copay Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
Abilify MaintenaView full Abilify Maintena profile
CobenfyView full Cobenfy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.